Anika Therapeutics, Inc. ( (ANIK) ) has released its Q2 earnings. Here is a breakdown of the information Anika Therapeutics, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anika Therapeutics, Inc. is a global leader in the design, development, and commercialization of hyaluronic acid innovations, focusing on osteoarthritis pain management and orthopedic regenerative solutions. The company is headquartered in Bedford, Massachusetts.
Anika Therapeutics reported its second quarter 2025 financial results, highlighting a significant 41% increase in Regenerative Solutions revenue, driven by the Integrity Implant System and Hyalofast growth. However, the company experienced an 8% decrease in total revenue compared to the same period in 2024, primarily due to lower pricing for Monovisc and Orthovisc products.
Key financial metrics for the quarter included a revenue of $28.2 million, a gross margin of 51%, and a 17% reduction in operating expenses. Despite these efforts, Anika reported a loss from continuing operations of $4.6 million. The company remains optimistic about its Integrity platform, which received FDA clearance for new implant sizes, and plans to file the final PMA module for Hyalofast later this year.
The company’s international sales showed resilience, with a 5% sequential revenue growth, although year-over-year figures declined by 10% due to order timing and production issues. Anika is also advancing its Cingal product, with key activities underway for its NDA filing.
Looking ahead, Anika Therapeutics reaffirms its fiscal 2025 revenue and EBITDA guidance, while adjusting its long-term outlook to accommodate potential delays in the FDA review process for Hyalofast. The company is focused on resolving production challenges and enhancing plant capacity to support future growth.